Uncommon Cents Investing LLC Acquires 515 Shares of Danaher Co. (NYSE:DHR)

Uncommon Cents Investing LLC raised its stake in shares of Danaher Co. (NYSE:DHR) by 25.9% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,505 shares of the conglomerate’s stock after purchasing an additional 515 shares during the period. Uncommon Cents Investing LLC’s holdings in Danaher were worth $626,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Tsfg LLC lifted its stake in shares of Danaher by 733.3% in the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after acquiring an additional 88 shares during the period. Cape Investment Advisory Inc. acquired a new position in shares of Danaher in the 4th quarter worth approximately $25,000. BKM Wealth Management LLC acquired a new stake in shares of Danaher during the fourth quarter worth $27,000. Redmont Wealth Advisors LLC acquired a new stake in shares of Danaher during the first quarter worth $30,000. Finally, Wetzel Investment Advisors Inc. bought a new position in Danaher during the fourth quarter worth $29,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Stock Down 0.2 %

Shares of NYSE:DHR traded down $0.41 during midday trading on Thursday, hitting $240.00. 1,935,837 shares of the company’s stock were exchanged, compared to its average volume of 3,506,555. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.85 and a quick ratio of 1.51. Danaher Co. has a 12 month low of $182.09 and a 12 month high of $269.11. The company has a market cap of $177.77 billion, a PE ratio of 40.68, a price-to-earnings-growth ratio of 3.68 and a beta of 0.83. The stock has a 50 day moving average price of $255.67 and a 200-day moving average price of $246.91.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The firm had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.62 billion. During the same period in the previous year, the company posted $2.36 EPS. The company’s revenue for the quarter was down 2.6% on a year-over-year basis. On average, sell-side analysts anticipate that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be paid a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.45%. The ex-dividend date of this dividend is Friday, June 28th. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Analyst Ratings Changes

A number of brokerages have weighed in on DHR. Jefferies Financial Group initiated coverage on Danaher in a report on Monday, June 3rd. They set a “buy” rating and a $295.00 price target for the company. Citigroup raised their target price on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Barclays boosted their price target on Danaher from $260.00 to $270.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 24th. StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, June 25th. Finally, Robert W. Baird boosted their target price on shares of Danaher from $259.00 to $271.00 and gave the company an “outperform” rating in a research report on Wednesday, April 24th. Six research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat, Danaher presently has an average rating of “Moderate Buy” and a consensus target price of $268.67.

Insiders Place Their Bets

In other Danaher news, SVP Brian W. Ellis sold 4,000 shares of the stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $250.01, for a total value of $1,000,040.00. Following the completion of the sale, the senior vice president now owns 29,830 shares in the company, valued at approximately $7,457,798.30. The transaction was disclosed in a document filed with the SEC, which is available at this link. In related news, CEO Rainer Blair sold 9,005 shares of the firm’s stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $265.00, for a total transaction of $2,386,325.00. Following the completion of the sale, the chief executive officer now owns 106,990 shares in the company, valued at $28,352,350. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Brian W. Ellis sold 4,000 shares of the business’s stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $250.01, for a total transaction of $1,000,040.00. Following the completion of the transaction, the senior vice president now owns 29,830 shares in the company, valued at $7,457,798.30. The disclosure for this sale can be found here. Insiders have sold 148,783 shares of company stock valued at $37,536,717 in the last three months. 10.90% of the stock is currently owned by insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.